Home / Conditions / Lupus (SLE)
🤼 Systemic Lupus Erythematosus

Lupus (SLE): what you need to know

A plain-English guide covering what lupus is, how it feels, how doctors diagnose it, what labs are involved, what treatment looks like, and what to expect. Written for patients and anyone newly navigating this diagnosis.

1.5M+
Americans estimated to have lupus
9:1
female-to-male ratio in adults of reproductive age[3]
HCQ
hydroxychloroquine recommended for most patients with SLE unless contraindicated[2]
90%+
five-year survival since the 1980s, up from ~40% in the 1950s[2]
The basics

What is lupus?

Systemic lupus erythematosus, almost always called SLE or simply lupus, is a chronic autoimmune disease. In autoimmune disease, the immune system mistakenly attacks healthy tissue in the body. In lupus, that attack can happen in almost any organ, which is part of what makes it so variable from person to person.[1]

The word "systemic" matters here. Lupus is not just a skin condition or just a joint condition. It can affect the skin, joints, kidneys, heart, lungs, blood cells, brain, and other organs at the same time or at different points in the disease course.[1] For some people lupus is mild and manageable. For others it is more serious, particularly when the kidneys are involved.

One of the hallmarks of lupus is the production of antinuclear antibodies, or ANAs. These are proteins the immune system makes that mistakenly target the body's own cell nuclei. They are found in virtually all people with lupus at some point, though they also appear in some healthy people and in other conditions, so a positive ANA alone does not diagnose lupus.[1]

The clinical course of lupus tends to be unpredictable. Most people experience periods of more active disease, called flares, alternating with periods of relative calm. The goal of treatment is to reduce the frequency and severity of flares, protect organs from damage, and allow people to live as full a life as possible.[2]

Who gets lupus? Lupus is far more common in women than men, with a ratio of roughly 7 to 15 women for every man among adults of reproductive age.[3] It most often begins between the ages of 16 and 55, though it can appear at any age. It is also more common in people of Black, Hispanic, Asian, and Native American backgrounds than in White Americans, and tends to be more severe in these groups as well.[3] The reasons involve a combination of genetic factors, environmental exposures, and, critically, social determinants of health, including access to quality care, socioeconomic factors, and systemic inequities in the healthcare system. Biology alone does not explain these differences.
What it feels like

Symptoms

Lupus is sometimes called "the great imitator" because its symptoms can look like many other conditions. No two people with lupus have exactly the same experience. Symptoms can vary widely, change over time, and some may be present for years before a diagnosis is made.[1]

Malar (butterfly) rash
A red or pinkish rash across the cheeks and bridge of the nose, sparing the nasolabial folds. Often triggered or worsened by sun exposure. One of the most recognizable features of lupus, though not everyone gets it.[1]
Fatigue
Fatigue is extremely common and among the most disabling symptoms people with lupus experience. It does not always track closely with how active the disease appears on blood tests.[1]
Joint pain and swelling
Arthritis and joint pain affect more than 90 percent of people with lupus and are often among the earliest symptoms. The joint involvement tends to be migratory and symmetric. Unlike rheumatoid arthritis, lupus joint disease rarely causes erosive bone damage on X-rays.[4]
Photosensitivity
Many people with lupus are unusually sensitive to sunlight or UV light, which can trigger or worsen rashes and sometimes provoke systemic flares. Even fluorescent indoor lighting can affect some people.[1]
Oral and nasal ulcers
Sores in the mouth or nose that are typically painless, unlike cold sores. They may go unnoticed. Nasal ulcers rarely lead to septal perforation, and this occurs only in more severe or longstanding disease.[4]
Hair loss
Patchy or diffuse hair thinning is common during flares. This is usually non-scarring and tends to regrow when disease activity is controlled, though scarring from discoid lupus lesions on the scalp can cause permanent loss in that area.[4]
Raynaud's phenomenon
Fingers or toes that turn white, then blue, then red in response to cold or stress. This vasospastic response occurs in up to 50 percent of people with lupus and can sometimes precede the full diagnosis by years.[4]
Chest pain and breathing symptoms
Inflammation of the lining around the lungs (pleuritis) or heart (pericarditis) causes sharp, positional chest pain. Pericarditis is the most common cardiac manifestation, occurring in about 25 percent of patients at some point.[4]

It is also worth knowing that cutaneous lupus, lupus affecting primarily the skin, can occur with or without full systemic involvement. Someone with discoid lupus, for example, may have significant skin disease without the kidney, blood, or other organ involvement seen in SLE. The two can overlap, but they are not the same, and many people with skin-limited lupus never develop systemic disease.[4]

Kidney involvement is one of the most important manifestations of lupus to know about. It is clinically apparent in roughly 50 percent of patients at some point and is a major cause of serious long-term complications.[5] Because kidney disease in lupus can be silent early on, with no symptoms you would notice, regular urine and kidney function testing is an important part of lupus care even when you feel well.

Neuropsychiatric symptoms are less talked about but real. Lupus can cause cognitive difficulties, mood changes, headaches, seizures, and in some cases psychosis. These neurologic manifestations can be caused by the disease itself or by medications, and distinguishing between the two can be challenging.[4]

Blood count changes are also common. Lupus often causes low white blood cell counts (leukopenia), anemia, and sometimes low platelets. These are part of how lupus behaves, not necessarily side effects of medication.[4]

When to seek urgent care: Contact your doctor promptly if you develop severe chest pain or shortness of breath, blood in the urine or marked swelling of the legs, high fever (especially while on immunosuppressive medication), sudden neurological symptoms such as confusion, vision changes, or weakness, or any rapidly worsening symptoms. Infection is a major cause of serious illness in lupus patients, and distinguishing a lupus flare from infection is clinically important.[4]
Getting a diagnosis

How lupus is diagnosed

Lupus does not have a single test that confirms or rules it out. The diagnosis is made by an experienced clinician who puts together the full picture: your symptoms, physical examination findings, and laboratory results, after ruling out other conditions that can look similar.[2] This process can take time, sometimes months or years, which is one of the most frustrating aspects of living with this disease before a name is finally put to it.

1
History and physical examination
Your doctor will ask about a wide range of symptoms across every organ system. Key areas of focus include skin rashes (especially ones triggered by sun), oral or nasal ulcers, joint pain, chest pain, shortness of breath, neurological symptoms, prior miscarriages, and any medications you have taken that could cause drug-induced lupus. A thorough head-to-toe physical examination follows. Your doctor will also ask about any medications you take, because some drugs can cause drug-induced lupus, a condition that shares features with SLE but resolves when the offending drug is stopped and is considered a distinct entity from classic SLE.[2]
2
Laboratory testing
A standard lupus workup includes a complete blood count (looking for anemia, leukopenia, and low platelets), kidney function and urinalysis (looking for protein, blood, and casts in the urine), an ANA test, and if the ANA is positive, additional specific antibodies including anti-dsDNA and anti-Sm. Complement levels (C3 and C4), antiphospholipid antibodies, and inflammatory markers are also typically checked.[2]
3
Classification criteria as a clinical guide
Rheumatologists often refer to formal classification criteria when evaluating a patient for lupus. The most widely used today is the 2019 EULAR/ACR criteria, which assigns points across clinical and immunologic categories. A score of 10 or more, together with a positive ANA, supports a classification of SLE. These criteria were developed primarily for research purposes, not as a diagnostic checklist, but they help systematically document which features of lupus are present.[2]
4
Additional testing when indicated
Depending on the clinical picture, further testing may include imaging of the chest or heart, an echocardiogram, MRI of the brain if neurological symptoms are present, or a kidney biopsy if lupus nephritis is suspected. A kidney biopsy tells rheumatologists and nephrologists which class of nephritis is present and guides the choice of treatment.[5]
5
Ruling out conditions that look like lupus
Many conditions can mimic lupus, including rheumatoid arthritis, Sjogren's disease, mixed connective tissue disease, viral infections (especially Epstein-Barr virus and parvovirus), fibromyalgia, and others. Distinguishing lupus from these alternatives is part of the diagnostic process and is one reason diagnosis can take time.[2]
Important: about classification criteria and diagnosis. Patients often hear about "criteria" and wonder whether they need to meet all of them to have lupus. The classification criteria are primarily tools for research, not rigid diagnostic gatekeepers. A rheumatologist can and does diagnose lupus in patients who do not meet the formal criteria if the clinical picture is convincing. Equally, some patients may have features that suggest lupus but not yet enough to confirm it. These patients are followed closely over time, as lupus can evolve and become clearer.[2,20]
Understanding your labs

Lab results explained

Lupus involves a wide range of blood and urine tests, and keeping track of what each one means can be overwhelming. Here is a plain-English guide to the most important ones.

Test What it measures What to know
ANA Antinuclear antibodies, the main screening test for lupus Positive in virtually all patients with lupus at some point. However, a positive ANA is also common in healthy people and in many other conditions, so it must always be interpreted alongside your symptoms and other tests.[2]
Anti-dsDNA Antibodies to double-stranded DNA Present in roughly half to two-thirds of people with lupus depending on the population studied, and highly specific for the diagnosis. Levels often rise and fall with disease activity, particularly kidney disease. A rising anti-dsDNA can sometimes signal increasing disease activity, particularly in patients with kidney involvement, though not all rises predict a clinical flare.[13]
Anti-Sm Antibodies to the Smith antigen Found in about 30 percent of patients with lupus. When present, it is highly specific for SLE, meaning it is rarely seen in other conditions. Unlike anti-dsDNA, anti-Sm levels do not reliably track with disease activity.[2]
Complement (C3 and C4) Proteins that are part of the immune system Low C3 and C4 are common in active lupus and indicate that the complement system is being consumed by immune complexes. A falling complement, especially alongside a rising anti-dsDNA, can sometimes signal increasing disease activity. Checking these together is more informative than either alone.[1]
CBC (complete blood count) Counts of red cells, white cells, and platelets Lupus commonly causes low white blood cells (leukopenia, especially lymphopenia), mild anemia, and occasionally low platelets. These are features of the disease itself and are monitored at every visit.[4]
Urinalysis and urine protein Screens for kidney involvement Protein, blood, or cellular casts in the urine can signal lupus nephritis, sometimes before any symptoms develop. This is why regular urine testing is part of routine lupus care even when you feel well.[2]
ESR and CRP General markers of inflammation ESR tends to rise with lupus activity. CRP behaves differently in lupus than in many other inflammatory diseases, it is often only mildly elevated or even normal even during active flares, because type I interferon (a cytokine elevated in lupus) suppresses CRP production in the liver. A markedly elevated CRP deserves careful clinical interpretation, it may suggest infection, serositis, or active synovitis, and does not by itself rule lupus activity in or out.[14]
Antiphospholipid antibodies Antibodies associated with clotting risk Present in up to 30 to 40 percent of people with lupus. Having these antibodies increases the risk of blood clots in veins and arteries and is associated with pregnancy complications. Not everyone with these antibodies develops clinical problems. However, some patients with lupus and persistently positive antiphospholipid antibodies develop antiphospholipid syndrome (APS), a condition associated with blood clots in veins or arteries, stroke or TIA at a young age, and recurrent pregnancy loss. APS requires specific management to reduce these risks.[2]
Anti-Ro/SSA and anti-La/SSB: These antibodies are present in a meaningful minority of people with lupus, though they are more commonly associated with Sjogren's disease.[1] They are particularly important in pregnancy because anti-Ro/SSA can cross the placenta and cause neonatal lupus and, in rare cases, congenital heart block in the baby. If you have these antibodies and are pregnant or planning pregnancy, your rheumatologist and obstetrician will want to monitor the baby's heart rate during pregnancy.
What treatment looks like

Treatment

Lupus treatment is highly individualized. The same diagnosis can look very different in two people, and the approach to treatment is tailored to which organs are involved, how active the disease is, and how you have responded to therapy in the past. The goals are to reach remission or low disease activity, protect organs from damage, minimize medication side effects, and maintain quality of life.[2]

For virtually everyone
Hydroxychloroquine (Plaquenil)
Hydroxychloroquine is recommended for virtually all patients with lupus, regardless of disease severity. It is an antimalarial drug that was repurposed for lupus decades ago and has been shown to reduce flare rates, improve survival, lower the risk of blood clots, and help protect against organ damage over time.[6,19] It typically takes two to three months before the clinical effects are fully felt. Current guidelines recommend dosing based on your actual body weight, typically 5 mg per kilogram per day, with a maximum of 400 mg daily, rather than using a fixed dose for everyone. The main long-term concern is rare retinal toxicity. Baseline ophthalmology screening should happen when you start the medication, with ongoing retinal surveillance, using sensitive testing such as OCT, at intervals your eye doctor recommends based on how long you have been on the drug and your individual risk factors.
Key point: Stopping hydroxychloroquine is associated with a significantly higher risk of disease flare, even in people who have been stable for years.[2]
For mild to moderate disease
NSAIDs and low-dose glucocorticoids
For patients with predominantly skin, joint, and mucosal involvement, hydroxychloroquine is often enough. When it is not, short courses of low-dose prednisone (or equivalent) and nonsteroidal anti-inflammatory drugs can help manage flares. Glucocorticoids work quickly and are often used as a bridge while slower-acting medications take effect. However, long-term or high-dose glucocorticoid use carries significant risks, including bone loss, weight gain, high blood pressure, diabetes, and infection, so the goal is always to use the lowest effective dose for the shortest possible time.[1]
Steroid-sparing agents
Immunosuppressants
When disease cannot be adequately controlled with hydroxychloroquine alone, or when glucocorticoids cannot be tapered to a safe long-term dose, an immunosuppressant is added. The choice depends on which organs are involved and your individual health situation. These medications take weeks to months to reach their full effect and require regular blood and urine monitoring.[1]
Common examples: azathioprine (Imuran), mycophenolate mofetil (CellCept), methotrexate, cyclophosphamide (for severe disease, especially nephritis)
Targeted biologics
Biologic therapies
Several biologic medications have been approved for lupus in recent years, representing a major advance over older treatments. They target specific parts of the immune system rather than suppressing it broadly, which may allow more targeted treatment, though they still carry important risks and require monitoring.[1]
Belimumab (Benlysta): Blocks a protein called BAFF that helps autoreactive B cells survive. Approved for both non-renal and renal lupus. Takes three to six months to reach full effect.

Anifrolumab (Saphnelo): Blocks the type I interferon receptor. Approved for moderate to severe lupus without active kidney disease. Particularly effective for skin and joint involvement.[9]

Voclosporin (Lupkynis) and obinutuzumab: Both are approved specifically for active lupus nephritis in combination with other agents. They are not general lupus biologics for all patients.
For severe or organ-threatening disease
Induction therapy
When lupus causes serious organ involvement, particularly kidney disease or central nervous system disease, more intensive initial treatment is needed to bring the disease under rapid control and prevent permanent organ damage. This typically involves high-dose glucocorticoids combined with an immunosuppressant such as mycophenolate or cyclophosphamide. Once the disease is controlled, therapy is stepped down to less intensive maintenance treatment.[1,5]
Medication safety basics. Do not stop hydroxychloroquine without first discussing it with your rheumatologist, as stopping is strongly associated with flares even in people who feel well. If you are on immunosuppressants, regular blood and urine monitoring is essential throughout treatment. Contact your care team promptly if you notice vision changes, persistent fever, new or worsening leg swelling, foamy or dark urine, chest pain, or any new neurological symptoms such as headache, confusion, or weakness.[1]
Sun protection is part of treatment. This is an important part of disease management. UV light can trigger systemic lupus flares, not just skin rashes. Broad-spectrum sunscreen with SPF 50 or higher, protective clothing, and avoiding prolonged direct sun exposure are genuinely important disease-modifying behaviors in lupus.[1][2] Some patients are also sensitive to certain indoor light sources, though this varies considerably between individuals.
Smoking and lupus. Smoking is associated with more active disease, poorer response to hydroxychloroquine, reduced effectiveness of belimumab, and a higher baseline cardiovascular risk that lupus already elevates.[1] Quitting smoking is one of the most meaningful steps a person with lupus can take outside of taking their medications.
Staying on track

Monitoring and follow-up

Because lupus can change over time and affect almost any organ without warning, regular monitoring is essential, even when you feel well. The interval between visits depends on your disease activity, but most rheumatologists aim for every three to four months for most patients, with more frequent visits during active disease or when starting new medications.[8]

What is monitored How often / what to know
Blood tests (CBC, kidney function, anti-dsDNA, complement) At least every six months when stable; more frequently with active disease. Anti-dsDNA and complement levels are the most useful markers for predicting and detecting flares.[13]
Urinalysis and urine protein Urine testing is checked regularly because kidney involvement can develop silently, sometimes before any symptoms appear. In people without known kidney disease, screening for proteinuria is recommended at least every six to twelve months; more frequently if there are signs of renal involvement. Your rheumatologist will determine the right frequency for you.[5,8]
Eye examination (hydroxychloroquine monitoring) Baseline ophthalmology screening is recommended when starting hydroxychloroquine. Ongoing retinal screening, using sensitive modalities such as spectral-domain OCT and visual field testing, is generally recommended no later than five years after starting the drug in low-risk patients, and sooner for those with higher risk. The exact schedule is determined by your ophthalmologist based on your dose, duration of use, and individual risk factors.[7]
Blood pressure and cardiovascular risk Lupus significantly increases cardiovascular risk through inflammation and sometimes through medications. Blood pressure, cholesterol, blood sugar, smoking status, and weight are all part of comprehensive lupus care.[1]
Bone density Glucocorticoid use and the disease itself increase osteoporosis risk. Bone density testing and supplementation with calcium and vitamin D are often part of long-term management.[1]
Vaccinations Staying up to date on vaccines is important because lupus and many lupus treatments affect immune function. Flu, pneumonia, HPV, hepatitis B, and COVID-19 vaccines are generally safe and recommended. Live vaccines are usually avoided while on most immunosuppressive therapies.[1]
If you get sick or need emergency care: Immunosuppressants and biologic medications are often temporarily held during serious infections. Hydroxychloroquine is generally continued unless your treating clinician advises otherwise. Do not stop any medications on your own, but contact your rheumatology team promptly if you develop high fever, signs of serious infection, or need to be hospitalized. Make sure any treating physician knows your full medication list.[1]
Disease activity scores. Your rheumatologist may use a validated scoring tool called the SLEDAI-2K to formally measure disease activity at each visit. This assigns points across different organ systems to give an overall activity number. Your rheumatologist may use formal disease activity scores to track lupus over time and guide treatment decisions. These tools are also used in clinical trials to assess treatment response.[15]
Living with lupus

The bigger picture

Lupus is a disease that extends well beyond your joints and skin. Understanding the broader impact helps you and your care team stay ahead of complications rather than reacting to them after the fact.

Cardiovascular risk is significantly elevated in lupus. People with lupus have a higher risk of heart disease, stroke, and heart failure, driven partly by inflammation and partly by the long-term effects of glucocorticoid use and other risk factors. This is one reason why controlling disease activity matters so much beyond just how you feel today.[2] Managing blood pressure, cholesterol, smoking, and blood sugar becomes especially important. Regular preventive care is especially important in lupus.

Fatigue is real and complex. Lupus fatigue is not simple tiredness and is not always directly tied to how active your disease appears on blood tests. It can be driven by inflammation, poor sleep, depression, fibromyalgia (which co-occurs in a meaningful proportion of lupus patients), and anemia, among other causes.[4] Addressing each contributor systematically, rather than attributing all fatigue to lupus activity alone, tends to produce better outcomes.

Mental health matters. Depression and anxiety are significantly more common in people with lupus than in the general population, and they are associated with worse outcomes. This is not a character issue or a reaction to being sick. Inflammatory disease affects brain chemistry, medications can affect mood, and the unpredictability of chronic illness takes a real toll. Discussing mental health with your rheumatologist or seeking support from a mental health professional is part of comprehensive care.[4]

Infection risk is a real consideration. Serious infections affect a substantial portion of lupus patients over the course of their disease, and they are among the leading causes of hospitalization and death, particularly early in the disease course.[2] This risk comes from both the disease itself (which affects immune function) and from immunosuppressive medications. Staying up to date on vaccines, reporting fevers promptly, and avoiding sick contacts when your immune system is suppressed all matter.

Pregnancy planning requires advance coordination. Some lupus medications are not safe during pregnancy, including mycophenolate mofetil and cyclophosphamide, and must be stopped well before conception. Other medications, including hydroxychloroquine, are considered safe and are often continued. Pregnancy in lupus is manageable but requires careful planning and close monitoring by both your rheumatologist and a high-risk obstetrician. Pregnancy should ideally be planned during a period of low disease activity, with the disease stable for at least six months before conception. Do not stop any lupus medications on your own if you become pregnant or are trying to conceive, as some medications require a planned, supervised transition.[1]

At your next appointment

Questions to ask your doctor

Lupus appointments can feel rushed. These questions are worth writing down and bringing with you.

→What is my disease activity right now, and what does that mean for my risk of a flare?
→What do my recent lab results show, especially my anti-dsDNA and complement levels?
→Are there any signs of kidney involvement in my urine tests?
→Is my current treatment plan working, and is there anything we should change?
→What are the side effects I should watch for with my current medications?
→Am I due for a bone density scan or any cardiovascular screening?
→Which vaccines should I get, and are there any I should avoid given my medications?
→If I want to become pregnant, what do I need to do to prepare?
→If I have a flare before my next appointment, what should I do and what is the threshold for calling?
→Are there any clinical trials I might be eligible for?
Prepare for your visit
Use the Appointment Prep tool to build a full symptom log, medication list, and question sheet to bring to your doctor.
→
Stay updated
Get notified when new condition guides are published
No spam. Unsubscribe any time.
Common questions

FAQ

What is the difference between lupus and other autoimmune diseases? ▼

The main distinguishing feature of lupus is how many different organs it can affect simultaneously. While diseases like rheumatoid arthritis primarily affect joints and Sjogren's disease primarily affects glands, lupus is truly systemic, the kidneys, heart, lungs, brain, blood, and skin can all be involved. The presence of anti-dsDNA and anti-Sm antibodies is also relatively specific to lupus compared with other autoimmune conditions.[1]

Lupus can overlap with other autoimmune diseases, and conditions can look very similar to each other early on, which is one reason diagnosis sometimes takes time. Some patients have features of both lupus and Sjogren's disease, or both lupus and rheumatoid arthritis (a pattern sometimes called "rhupus"). Mixed connective tissue disease is a related condition with overlapping features of lupus, scleroderma, and myositis.

My ANA is positive but my rheumatologist says I don't have lupus. Why? ▼

A positive ANA is very common and does not equal a lupus diagnosis. ANA testing is positive in nearly all people with lupus, but it is also positive in many healthy people, in other autoimmune conditions, and sometimes transiently after infections. Studies suggest that up to 20 percent of healthy adults can have a low-positive ANA.[2]

What matters is the combination of the ANA result with your symptoms, physical examination findings, and other laboratory tests. Lupus is a clinical diagnosis, and a positive ANA is the starting point of the evaluation, not the conclusion of it. If your ANA is positive but your rheumatologist does not diagnose lupus, that likely means the broader picture does not fit the diagnosis, which is a good outcome, not a missed one.

Can lupus go into remission? ▼

Yes, though complete remission is less common than partial remission or low disease activity. Studies suggest that somewhere between 7 and 25 percent of people with lupus achieve remission for at least one year with treatment. Sustained remission lasting five or more years is less common, occurring in perhaps 2 to 7 percent of patients.[11,12]

It is important to understand that remission in lupus means the disease has become quiet, but the condition's tendency toward activity remains. This is why most patients need to continue some form of treatment, particularly hydroxychloroquine, even in remission, because stopping medication is strongly associated with relapse.[19] In some patients who achieve sustained remission, doses of other medications may be carefully reduced over time, but this is done gradually and with close monitoring.

Is lupus hereditary? Will my children get it? ▼

Genetics plays a meaningful role in lupus, but lupus is not caused by a single gene and does not follow a simple inheritance pattern. Having a parent or sibling with lupus does increase your risk compared with the general population, but most first-degree relatives of people with lupus will never develop it.[18]

Current research has identified more than 100 genetic variants associated with lupus susceptibility, but genetic factors account for only about 30 to 40 percent of disease risk. Environmental triggers, hormonal factors, and other elements all play a role. The risk of any individual child developing lupus because a parent has it is relatively low, though somewhat higher than baseline.[18]

Can I get pregnant with lupus? ▼

Yes. Many people with lupus have successful pregnancies. However, lupus pregnancy is considered high-risk and requires careful planning and monitoring. The disease should ideally be stable for at least six months before conception, because active lupus at the time of conception is associated with worse pregnancy outcomes.[2]

Some medications used to treat lupus are not safe during pregnancy, including mycophenolate mofetil and cyclophosphamide, and must be stopped well in advance. Hydroxychloroquine is generally considered safe during pregnancy and is usually continued. Methotrexate, if used, must also be stopped before conception. If you are considering pregnancy, talk to your rheumatologist well in advance so your treatment can be adjusted accordingly.[1]

Women with anti-Ro/SSA antibodies require additional monitoring during pregnancy because these antibodies can cross the placenta and cause neonatal lupus or, in rare cases, congenital heart block in the baby.[1]

My labs look fine but I feel terrible. Is that possible? ▼

Yes, and this is one of the most common frustrations people with lupus describe. Some symptoms in lupus, including fatigue, diffuse pain, sleep problems, and brain fog, do not always track with inflammatory activity. They can be significant and disabling even when blood tests look normal.[4]

These symptoms can be driven by co-occurring fibromyalgia, depression, sleep disorders, or deconditioning rather than active inflammation, which means they may not respond to increasing immunosuppression. Addressing each potential contributor separately, rather than assuming all symptoms are from active lupus, is usually the more effective approach. If you feel this way, be direct with your rheumatologist so they can help investigate the cause.

What is the long-term outlook for lupus? ▼

The outlook for lupus has improved dramatically over the past 70 years. Five-year survival is now greater than 90 percent in most settings, compared with roughly 40 percent in the 1950s. This improvement reflects earlier diagnosis, better treatments, and more careful monitoring.[16]

That said, lupus still carries a two- to fivefold higher mortality rate than the general population. The main causes of early death are severe organ involvement (particularly kidney and brain disease) and serious infections related to immunosuppression. Later in the disease course, cardiovascular disease becomes increasingly important. Factors associated with worse outcomes include kidney disease, male sex, young age at diagnosis, Black race, and the presence of antiphospholipid antibodies.[16]

For most people with lupus who receive appropriate care, the goal is a long life with good quality of life, managing the disease as a chronic condition rather than being defined by it.

Clinical Trials
New lupus treatments are being studied right now
Clinical trials for SLE are actively recruiting patients at sites across the country. Participating in a trial gives you access to emerging therapies and contributes to advances that help future patients. Many trials are free to join.
Browse lupus trials →
Sources
  1. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83:15.
  2. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78:1151.
  3. Izmirly PM, Parton H, Wang L, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol 2021; 73:991.
  4. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.
  5. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64:797.
  6. Cai T, Zhao J, Yang Y, et al. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. Lupus 2022; 31:1714.
  7. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.
  8. Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J Rheumatol 2013; 40:630.
  9. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 2020; 382:211.
  10. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.
  11. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021; 8.
  12. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467.
  13. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2342.
  14. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59:1814.
  15. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288.
  16. Lee YH, Song GG. Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects. Lupus 2024; 33:929.
  17. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62:863.
  18. Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013; 72 Suppl 2:ii56.
  19. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150.
  20. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.
Disclaimer: This page was created by Mahiar Rabie, MD, MS using current medical evidence and guideline-based sources. It is intended to inform and educate, not to replace the advice, diagnosis, or treatment of a qualified physician. Always consult your doctor with questions about your specific condition and treatment.